Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group LSE:RENE London Ordinary Share GB00B0DZML60 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 1.95p 1.90p 2.00p 1.975p 1.95p 1.95p 550,995 14:00:19
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -18.2 -0.5 - 61.71

Reneuron (RENE) Latest News

More Reneuron News
Reneuron Takeover Rumours

Reneuron (RENE) Share Charts

1 Year Reneuron Chart

1 Year Reneuron Chart

1 Month Reneuron Chart

1 Month Reneuron Chart

Intraday Reneuron Chart

Intraday Reneuron Chart

Reneuron (RENE) Discussions and Chat

Reneuron Forums and Chat

Date Time Title Posts
13/11/201709:10ReNeuron - a leading, clinical-stage stem cell business5,377
07/8/201708:10Interpretating Neil Woodfords. ..5
02/8/201711:05Interesting article...albeit lengthly5

Add a New Thread

Reneuron (RENE) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-11-21 16:35:081.9550,816990.91UT
2017-11-21 16:25:211.9510,000195.00O
2017-11-21 16:24:432.005,000100.00O
2017-11-21 14:57:191.9950,000995.00O
2017-11-21 13:44:241.9911,000218.90O
View all Reneuron trades in real-time

Reneuron (RENE) Top Chat Posts

Reneuron Daily Update: Reneuron Group is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker RENE. The last closing price for Reneuron was 1.95p.
Reneuron Group has a 4 week average price of 1.63p and a 12 week average price of 1.55p.
The 1 year high share price is 3.50p while the 1 year low share price is currently 1.55p.
There are currently 3,164,618,541 shares in issue and the average daily traded volume is 900,221 shares. The market capitalisation of Reneuron Group is £61,710,061.55.
deutsch3: We need to inject some stem cells into the Management to get the share price moving. It appears as if they are helping 'someone?' get a bundle out!
top tips: IMMUPHARMA (IMM) Potential blockbuster Lupuzor Phase III results due Q1 2018. Only other similar drug Benlysta was bought out from HGSi by GSK in 2012 for $3.6 billion for 50% stake valuing Benlysta around $7 billion (and IMM's Lupuzor appears to be safer and more efficaceous than Benlysta). $7 billion buyout of IMM gives £39.70 share price against current 54p, or 70+ bagger !!! Potential blockbuster Lupuzor has 'Fast Track' and 'SPA' status from US FDA, so could market launched in 2018. Tim McCarthy (IMM's Chairman) 14/3/2017: "There's going to be a fantastic return on investment for anybody who invests in ImmuPharma...This (Lupuzor) is going to be a multi-billion dollar drug, its as simple as that...This will absolutely be a multi-billion dollar drug." 4 min 40 sec. hTTps://
dickbush: Thanks,algernon2 A very professional and positive presentation. However, he and the company seem to continue to have a major credibility problem-as judged by the share price. Despite record highs for the stockmarket, the share price is at an all-time low with holders, apparently, willing to sell no matter what the bid price.
dogwalker: 'Results' are a list of projects being worked on. The real news - or results really - come at times when they discover something or someone offers money. The consequence of today's RNS , so far, is that the share price trajectory is maintaining its 'going down the drain' path.Of course that can change suddenly, & I certainly hope it will .
johnb5: Huge potential here, but the market has been bitten to many times by jam tomorrow AIM companies. Although RENE have cash now, its not enough to take these therapies through to commercialisation, even if they do get approval. That's the problem with the share price. I'll continue on the side lines for the time being GLA.
dickbush: This video should hasten the day when RENE makes a public statement on the outcome of the trial. It doesn't look as though lower doses of stem cells have improved sight. So, we have to hope that the one million cell group had a better outcome. If not, the company will have to suggest yet higher doses may be needed in the next trials, always assuming they are going to continue. Today's share price decline seems to me to be entirely reasonable. There has been a suspicion for a long time that RENE would fail to achieve success with any of its trials, and this probability has just risen. I am a holder but I've always known that this was either a ten-bagger or a bust. So, I'm disappointed but not surprised. I imagine that the CEO will be fielding a few questions from major shareholders this morning, particularly Woodford.
alimo: Will never understand why prices go up and down on such small trading volume - I mean there are over 3bn shares in issue. I topped up a little today thinking there's RP news due in first half of this year, maybe MH will want to speak about it in Edinburgh next week. Someone is holding this back, though how they do it when Woodford , Toscafund, and Aviva are aboard and positive about it, beats me. Also Olaf H the CEO spent £10,000 adding 346,644 shares on 14th Dec 2016 to make his total 669,422, and even Michael H who's speaking on Wednesday, bought another 250,000 this week taking him to a total of 2,008,471. These two both have big share options exercisable subject to the achievement of the following performance conditions: 1) When the first patient is administered with a ReNeuron cell therapy in a sixth clinical trial, one third of the options will vest. 2) When the fourth clinical trial of a ReNeuron cell therapy completes, one third of the options will vest. 3) If the Total Shareholder Return (TSR) of the Company meets or exceeds that of the FTSE AIM Healthcare Index in any given three year period from the date of grant, one third of the options will vest. The vesting criteria for the TSR-related performance condition above will also apply on a proportionate basis to TSR-related performance conditions attaching to prior share option grants under the LTIP. Well, perhaps someone here understands what the above means and what the share price will have to be at before they get the big bucks. Olaf H's options pot amounts to 33m+ shares, and Michael H's pot is 29m+. In the meantime they get big salaries while our shares languish in sweeties land. We already have come a long long way and are nearer, and getting nearer every day, to the good news outcomes the company was floated for at 25p back in Aug 2005 and reaching 46p in Jan 2007. Investors in those days must must have had a real long term vision for RENE. Hopefully our CEO and CFO have the same vision to turn our company share price back up to these dizzy levels, without selling us out to be gobbled up by the AZNs of this world, before adequate payback for the 20 years of loyalty.
city chappy: ReNeuron gets Woodford's backing as it raises £68mln 12:56 10 Jul 2015 Olav Hellebø, Renueron’s chief executive, said it is the largest funding by a cell therapy group anywhere this year. ReNeuron gets Woodford's backing as it raises £68mln Neil Woodford's interest in ReNeuron is increasing to 35.5% Star fund manager Neil Woodford has increased his stake in stem cell therapy group ReNeuron (LON:RENE) through backing a hefty fund raise at a premium to the share price. ReNeuron is raising £68.4mln of which Woodford Investment Management is putting up almost half. Woodford, one of the UK's best known money managers, was a star performer at Invesco before branching out on his own. He is a major backer of UK biotechs and the launch earlier this year of Patient Capital, a trust focused on small caps and start-ups, pulled in hundreds of millions in new money. Olav Hellebø, ReNeuron’s chief executive, said it was the largest funding by a cell therapy group anywhere this year, underlining its position in the burgeoning stem cell therapy arena. Woodford Investment Management’s stake will rise to 35.5% from 26.63% with its new shares, though has been granted a waiver from having to make a mandatory offer. Woodford paid 5p for the shares, a small premium to the closing price yesterday. The funds will be sufficient to pay for ReNeuron’s existing therapeutic programmes through to 2019 and also early development of a new exosome nanomedicine platform targeting cancer. Stem cell treatments for strokes and retinitis pigmentosa are now fully funded to the commercial stage. Hellebø said he was delighted with the amount raised through the placing. “The proceeds will enable us to rapidly exploit the potential of our CTX, hRPC and exosome nanomedicine therapeutic platforms, providing multiple opportunities to build value for our shareholders. Results from the ongoing phase II clinical trial of its stroke treatment are due in the first half of next year with phase I data for critical limb ischaemia expected around the same time. Regulatory approval was recently given for a phase I/II trial of its retinitis pigmentosa treatment with a phase II/II trial scheduled for 2017. The exosome nanomedicine platform was also generating promising early pre-clinical data, Hellebø said. There was a loss for the year to March of £8.91mln (2014: £7.07mln). Shares surged 20% to 5.86p on the news, reflecting the heavyweight backing. Michael Hunt, ReNeuron’s chief financial officer, told Proactive that a positive hit in any of the programmes going through trials would add significant value from where the company stands now. The placing would allow it to concentrate on taking its programmes through their trials and possible commercialisation without the distraction of funding worries. Shares rose 0.97p to 5.85p valuing the company at £104mln.
ftangftang: ReNeuron Group PLC (LON:RENE) had its stock rating reiterated as ‘Buy’ in a report released by analysts at N+1 Singer. N+1 Singer today set a target price of 10 on the company’s stock. According to the analyst this now indicates there is a potential increase of 222.58% from ReNeuron Group PLC’s current price of 3.1. LON:RENE Over the last twelve months ReNeuron Group PLC’s stock price has increased by 0% from 0.00 to 3.1 . There are currently 2,058,105,000 shares in issue with a current share value of 3.1 giving ReNeuron Group PLC a market capitalisation of 63.80M GBp . ReNeuron Group PLC (LON:RENE) has a 50 day moving average of 2.92 and a 200 day moving average of 4.41. The 52 week high for the share price is 6.5 while the 52 week low for the stock is 2.26. ReNeuron Group Plc (ReNeuron), based in the United Kingdom, is engaged in clinical-stage stem cell company. It is engaged in the research, development and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications. It develops cell-based therapies for disease conditions where the cells can be readily administered off-the-shelf to any eligible patient without the need for additional drug treatments. Its lead therapeutic candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. Its ReNcell products are used in academic and commercial sectors. Its ReN009 stem cell candidate is for the treatment of critical limb ischaemia, a side effect of diabetes. This treatment is in early-stage clinical development. Its ReN003 stem cell candidate is for the treatment of retina pigmentosa, a blindness-causing disease of the retina. This treatment is in late pre-clinical development HTTP:// cheers ft ft
Reneuron share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20171122 02:08:52